Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Woolworths Group Limited
  6. News
  7. Summary
    WOW   AU000000WOW2

WOOLWORTHS GROUP LIMITED

(WOW)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Woolworths : proposal to acquire API

12/01/2021 | 05:51pm EST

For personal use only

2 December 2021

ASX Market Announcements Office

Australian Securities Exchange

20 Bridge Street

Sydney NSW 2000

Woolworths Group non-binding proposal to acquire Australian Pharmaceutical

Industries

Please see attached an announcement regarding a proposal by Woolworths Group to acquire Australian Pharmaceutical Industries.

Authorised by: Kate Eastoe, Group Company Secretary

Woolworths Group Limited ABN 88 000 014 675

1 Woolworths Way, Bella Vista NSW 2153

For personal use only

Woolworths Group non-binding proposal to acquire Australian Pharmaceutical

Industries

Woolworths Group today announces that it has submitted the attached non-binding transaction proposal to Australian Pharmaceutical Industries Limited (API) to acquire 100% of its shares at a cash offer price of $1.75 per API share1 (total equity value of $872 million2) by way of a scheme of arrangement. The proposed offer price represents a premium of 20 cents per share (or 12.9%) over the price agreed between API and Wesfarmers under the scheme implementation deed announced on 8 November 2021.

In conjunction with its due diligence investigations, Woolworths Group is also willing to explore potential alternative control transaction structure options, such as a takeover bid with a minimum acceptance condition of 50.1% and/or other transaction structures that would be subject to receiving 50.1% API shareholder support, in order to deliver more value and/or certainty for API shareholders. Any such alternative transaction structure option would only be pursued by Woolworths Group with the approval of the API directors.

Woolworths Group is pleased to note that the Board of API has determined that the Woolworths Group proposal is, or is reasonably likely to be, a Superior Proposal (as defined in the Wesfarmers Scheme Implementation Deed). Woolworths Group will engage constructively with API to quickly finalise its due diligence enquiries.

API is one of Australia's leading health and beauty retailers and pharmaceutical distributors and is listed on the ASX. API is the parent company of the Priceline Pharmacy, Soul Pattinson Chemist, and Pharmacist Advice brands, and provides a range of retail services to its community pharmacy partners and company-owned Priceline retail stores. API also operates Clear Skincare, a non-surgical skincare clinic business, and Consumer Brands, a health and personal care business.

Strategic rationale and benefits for key stakeholders

Woolworths Group CEO, Brad Banducci, said: "There is a compelling strategic rationale to support Woolworths Group's acquisition of API. Health and wellness is a large, fast-growing category and API would be a fantastic addition to our food and everyday needs ecosystem. If successful, we will continue to support API's community pharmacy partners to deliver

  • The Woolworths Group proposal, consistent with the Wesfarmers proposal, allows for the payment of fully franked dividends of up to a maximum of 5 cents per API share. This includes the 2 cents per share dividend declared by API for the financial year ended 31 August 2021 and any other dividends or distributions declared or paid by API after 1 December 2021, with the cash consideration of $1.75 per share to be reduced by the cash component of any dividend.
    2 Based on 492.7 million API shares and 5.9 million API performance rights on issue as at 8 November 2021.

Woolworths Group Limited ABN 88 000 014 675

1 Woolworths Way, Bella Vista NSW 2153

For personal use only

better experiences for both customers and pharmacists. We will also work to strengthen API's wholesale and distribution business to ensure that all Australians continue to have timely, cost-effective access to a full range of PBS and other medicines, via their community pharmacy, regardless of where they live.

"We are strongly committed to supporting the community pharmacy model including pharmacy ownership and location rules to ensure pharmacies are well represented in all communities, especially in regional and remote parts of Australia.

"We also know that customer expectations across retail are evolving in areas like convenience, innovation, and value. Through our broad range of retail services and capabilities built over many years in areas such as digital; retail media; loyalty; payments; analytics; and supply chain, we can support the industry through this change and help create additional opportunities for community pharmacy partners to deliver further solutions for their customers.

"The combination of the two businesses is expected to lead to material shared benefits and synergies, much of which will be reinvested back into strengthening and growing API and its pharmacy partners. If successful, the transaction is expected to be funded from the Group's existing balance sheet capacity and to deliver attractive returns for Woolworths Group shareholders over the medium term.

"For API shareholders, the proposal represents a meaningful premium relative to the Wesfarmers scheme proposal announced on 8 November 2021."

Woolworths Group notes that the proposal is indicative, incomplete and non-binding and there is no certainty that the proposal, or any transaction, will be agreed or will proceed.

For further information contact:

Media: Woolworths Group Press Office: +61 2 8885 1033 media@woolworths.com.au

Investors and Analysts: Paul van Meurs, Head of Investor Relations: +61 407 521 651

Woolworths Group Limited ABN 88 000 014 675

1 Woolworths Way, Bella Vista NSW 2153

For personal use only

Confidential (unless waived)

Indicative, Incomplete and Non-Binding Proposal

1 December 2021

Kenneth Gunderson-Briggs

Chairman of the Board of Directors

Australian Pharmaceutical Industries Limited

250 Camberwell Rd

Camberwell Victoria 3124

Via email

Dear Kenneth,

PROPOSAL TO ACQUIRE 100% OF THE SHARES IN AUSTRALIAN PHARMACEUTICAL INDUSTRIES

Woolworths Group Limited (Woolworths Group) is pleased to provide this transaction proposal (Proposal) to acquire 100% of the shares in Australian Pharmaceutical Industries Limited (API) for A$1.75 per API share, and otherwise on terms substantially consistent with the terms proposed by Wesfarmers Limited (Wesfarmers) and API in the Scheme Implementation Deed between Wesfarmers and API, dated 8 November 2021 (Wesfarmers SID).

  • Strategic Rationale

In recent years, Woolworths Group has been evolving into a food and everyday needs retail ecosystem with the aim of providing our customers their food and everyday needs through convenient stores, services and a leading loyalty program. The ecosystem is supported by retail services, capabilities and platforms built over many years in areas like digital, data and supply chain.

Health and wellness is a large, attractive and fast growing category and the acquisition of API would be an attractive extension to our food and everyday needs ecosystem. We will continue to support API's community pharmacy partners to deliver better experiences for customers, pharmacists, and the team. We are confident that our experience in loyalty will enable us to further develop and enhance Priceline's Sister Club program to ensure that it remains Australia's leading health and beauty loyalty Program. We will also work to strengthen API's wholesale and distribution business to ensure that all Australians continue to have timely access to a full range of PBS and other medicines, via their community pharmacy, regardless of where they live.

Customer expectations across retail are evolving in areas like convenience, innovation, and value and we believe an acquisition of API by Woolworths Group will strengthen API's existing model of community pharmacy. It would retain the high quality service and strong health focus already provided by API's community pharmacy partners while providing them with access to our platforms and services capabilities in areas such as eCommerce; retail media, loyalty and payments; data and analytics; and supply chain.

  • Woolworths Group Limited

ABN 88 000 014 675

P

+61 2 8885 0000

1 Woolworths Way

E

companysecretariat@woolworths.com.au

Bella Vista, NSW 2153

W

woolworthsgroup.com.au

For personal use only

Woolworths Group supports the current ownership provisions and location rules which ensure that community pharmacies are well distributed throughout the community, especially in regional and remote parts of Australia. We are not seeking to change ‒ now or in the future ‒ the pharmacy ownership rules requirements or location rules.

  • Transaction Proposal

Consideration

Woolworths Group's Proposal is to acquire 100% of the shares in API for A$1.75 per API share in cash, less the cash amount of any "Permitted Dividends" (being fully franked dividends of up to a maximum of 5 cents per API share, including the 2 cents per share final dividend declared by API for the financial year ended 31 August 2021) and any other dividends or distributions declared or paid by API after the date of this letter (Offer Price) subject to the assumptions and conditions outlined in this letter.

The Offer Price represents compelling value for API shareholders, and we believe the Proposal represents a superior proposal to the Wesfarmers' scheme of arrangement which is offering API shareholders cash consideration of $1.55 per API share less the cash amount of any "Permitted Dividends".

Woolworths Group believes there is the potential to improve the Offer Price and enhance the terms of this Proposal with the benefit of due diligence.

Transaction Structure

Subject to the assumptions and conditions outlined in this letter, Woolworths Group proposes to acquire 100% of the shares in API by way of a scheme of arrangement (Woolworths Scheme) for the Offer Price and otherwise on substantially the same terms as the scheme of arrangement proposed by the Wesfarmers SID (Wesfarmers Scheme).

In conjunction with its due diligence investigations, Woolworths is also willing to explore potential alternative control transaction structure options, such as a takeover bid with a minimum acceptance condition of 50.1% and/or other transaction structures that would be subject to receiving 50.1% API shareholder support, in order to deliver more value and/or certainty for API shareholders.

Any such alternative transaction structure option would only be pursued by Woolworths with the approval of the API directors.

It is intended that any alternative transaction structure would facilitate the implementation of the Proposal on terms that are substantially equivalent to the Woolworths Scheme (other than for required differences to accommodate the alternative transaction structure with 50.1% API shareholder support).

Conditions to be Satisfied Prior to Announcement of a Binding Transaction

Woolworths Group has received necessary Board approvals to submit this Proposal.

  • Woolworths Group Limited

ABN 88 000 014 675

P

+61 2 8885 0000

1 Woolworths Way

E

companysecretariat@woolworths.com.au

Bella Vista, NSW 2153

W

woolworthsgroup.com.au

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Woolworths Ltd. published this content on 01 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2021 22:50:05 UTC.


ę Publicnow 2021
All news about WOOLWORTHS GROUP LIMITED
01/14U.S. grocery shortages deepen as pandemic dries supplies
RE
01/14Woolworths Places Buying Limits on Certain Products Amid Surging Omicron Cases
MT
01/12WOOLWORTHS : reinstates product limits on select categories nationwide
PU
01/11Australia's Retail Turnover Jumps to Record High in November 2021 on Black Friday Sales
MT
01/11Australia shares end lower as Omicron spreads, financials slide
RE
01/09Australia vows to 'push through' Omicron wave as infections cross 1 million
RE
01/09Australia vows to 'push through' Omicron wave as infections cross 1 million
RE
01/07Omicron Variant Hits Staff Attendance, Product Supply of Australian Supermarkets
MT
01/07Australian Shares Recoup Some Losses on Bargain Hunting
MT
01/06Woolworths Withdraws $609 Million Takeover Proposal for Australian Pharmaceutical Indus..
MT
More news
Analyst Recommendations on WOOLWORTHS GROUP LIMITED
More recommendations
Financials
Sales 2022 59 164 M 42 906 M 42 906 M
Net income 2022 1 429 M 1 036 M 1 036 M
Net Debt 2022 13 515 M 9 801 M 9 801 M
P/E ratio 2022 30,2x
Yield 2022 2,48%
Capitalization 42 337 M 30 571 M 30 703 M
EV / Sales 2022 0,94x
EV / Sales 2023 0,92x
Nbr of Employees 210 067
Free-Float -
Chart WOOLWORTHS GROUP LIMITED
Duration : Period :
Woolworths Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WOOLWORTHS GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 35,08 AUD
Average target price 37,28 AUD
Spread / Average Target 6,26%
EPS Revisions
Managers and Directors
Bradford Banducci Chief Executive Officer, MD & Executive Director
Stephen Harrison Group Chief Financial Officer
Gordon McKellar Cairns Independent Chairman
John Hunt Chief Information Officer
Rob McCartney Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
WOOLWORTHS GROUP LIMITED-6.87%30 849
WALMART INC.-0.52%399 272
SYSCO CORPORATION-1.09%39 828
THE KROGER CO.7.34%35 719
AHOLD DELHAIZE N.V.-0.73%34 414
TESCO PLC-0.71%29 798